Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $1

Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) had its target price boosted by JPMorgan Chase & Co. from $170.00 to $190.00 in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has an overweight rating on the specialty pharmaceutical company’s stock. Several other equities analysts have also weighed in on JAZZ. UBS […]

Related Keywords

Canada , United States , Philipl Johnson , Patricia Carr , St Germaindj Co , Covestor Ltd , Jazz Pharmaceuticals , News Ratings For Jazz Pharmaceuticals Daily , Assetmark Inc , Securities Exchange Commission , Royal Bank , Jazz Pharmaceuticals Trading Down , Cape Investment Advisory Inc , Analyst Recommendations For Jazz Pharmaceuticals , Jpmorgan Chase Co , Free Report , Moderate Buy , Pharmaceuticals Trading Down , Get Free Report , Exchange Commission , Investment Advisory , Spire Wealth Management , Wealth Management , Jazz Pharmaceuticals Daily ,